Adverse event (AE) reporting in oncology trials is required, but current practice does not directly integrate the child’s voice. The Pediatric Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) is being developed to assess symptomatic AEs via child/adolescent self-report or proxy-report. This qualitative study evaluates the child’s/adolescent’s understanding and ability to provide valid responses to the PRO-CTCAE to inform questionnaire refinements and confirm content validity
Symptomatic adverse events (AEs) in cancer trials are currently reported by clinicians using the Nat...
<p><b>Background:</b> Standardized reporting of treatment-related adverse events (AE) is essential i...
ObjectiveAdverse event (AE) reporting is crucial for determining safety of trials. Adverse events ar...
Adverse event (AE) reporting in oncology trials is required, but current practice does not directly ...
Context The National Cancer Institute created the Patient-Reported Outcomes version of the Common Te...
The National Cancer Institute’s Patient-Reported Outcomes version of the Common Terminology Criteria...
PURPOSE: To examine concordance in symptomatic adverse event (AE) grading using the Common Terminolo...
Background: In adult oncology, the practice of tracking symptoms and toxicities using patient-report...
Symptom monitoring using patient-reported outcomes (PROs) is not common in pediatric oncology, despi...
The National Cancer Institute (NCI) is developing a patient-reported version of its Common Terminolo...
Background: Using patient-reported outcomes for symptom monitoring in oncology has resulted in signi...
Background: Standardized reporting of treatment-related adverse events (AE) is essential in clinical...
Cancer affects one in every 500 children younger than 15 years in the UK, and around 1800 new cases ...
Systematic capture of the patient perspective can inform the development of new cancer therapies. Pa...
Background: Children with cancer suffer from numerous symptoms and side-effects, making supportive i...
Symptomatic adverse events (AEs) in cancer trials are currently reported by clinicians using the Nat...
<p><b>Background:</b> Standardized reporting of treatment-related adverse events (AE) is essential i...
ObjectiveAdverse event (AE) reporting is crucial for determining safety of trials. Adverse events ar...
Adverse event (AE) reporting in oncology trials is required, but current practice does not directly ...
Context The National Cancer Institute created the Patient-Reported Outcomes version of the Common Te...
The National Cancer Institute’s Patient-Reported Outcomes version of the Common Terminology Criteria...
PURPOSE: To examine concordance in symptomatic adverse event (AE) grading using the Common Terminolo...
Background: In adult oncology, the practice of tracking symptoms and toxicities using patient-report...
Symptom monitoring using patient-reported outcomes (PROs) is not common in pediatric oncology, despi...
The National Cancer Institute (NCI) is developing a patient-reported version of its Common Terminolo...
Background: Using patient-reported outcomes for symptom monitoring in oncology has resulted in signi...
Background: Standardized reporting of treatment-related adverse events (AE) is essential in clinical...
Cancer affects one in every 500 children younger than 15 years in the UK, and around 1800 new cases ...
Systematic capture of the patient perspective can inform the development of new cancer therapies. Pa...
Background: Children with cancer suffer from numerous symptoms and side-effects, making supportive i...
Symptomatic adverse events (AEs) in cancer trials are currently reported by clinicians using the Nat...
<p><b>Background:</b> Standardized reporting of treatment-related adverse events (AE) is essential i...
ObjectiveAdverse event (AE) reporting is crucial for determining safety of trials. Adverse events ar...